Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance

Rhea-AI Summary

Pulsenmore (NASDAQ: PLSM) announced a commercial services agreement with TLC Perinatal PA to incorporate Pulsenmore's Early Screening home ultrasound into a physician-directed hybrid prenatal care pathway in Maryland.

The agreement covers Silver Spring and Germantown sites and aims to combine home ultrasound, telehealth, and scheduled clinic visits to extend care beyond the clinic.

News Market Reaction

+0.87%

1 alert

+0.87% News Effect

+$322K Valuation Impact

$37M Market Cap

0.4x Rel. Volume

On the day this news was published, PLSM gained 0.87%, reflecting a mild positive market reaction. This price movement added approximately $322K to the company's valuation, bringing the market cap to $37M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Annual pregnancies managed: 2,000 pregnancies ACOG Clinical Consensus year: 2025

2 metrics

Annual pregnancies managed 2,000 pregnancies TLC Perinatal practice volume across two Maryland locations

ACOG Clinical Consensus year 2025 ACOG’s 2025 Clinical Consensus referenced for aligning care model

Market Reality Check

Price: $5.80 Vol: Volume 3769 is below the ...

low vol

$5.80 Last Close

Volume Volume 3769 is below the 20-day average of 18136 ahead of this news. low

Technical Price at 5.75 is trading below the 200-day MA of 6.12 and well under the 52-week high of 10.28.

Historical Context

2 past events · Latest: 2026-02-02 (Positive)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
2026-02-02	First U.S. engagement	Positive	+4.8%	First U.S. commercial services agreement for Pulsenmore ES after FDA clearance.
2026-01-26	Israel IVF agreement	Positive	+3.9%	Strategic Pulsenmore FC deal with Clalit, potentially $4.5M over five years.

Pattern Detected

Recent U.S. and Israeli commercial agreements have been followed by modestly positive single-day price reactions.

Recent Company History

In late January and early February 2026, Pulsenmore announced multiple commercial agreements tied to its home ultrasound platforms. On 2026-01-26, it disclosed a strategic Pulsenmore FC agreement with Clalit in Israel, potentially worth $4.5 million over five years after an 18‑month pilot. On 2026-02-02, it reported its first U.S. commercial engagement for Pulsenmore ES following FDA clearance. Both prior announcements saw positive one-day price moves, framing today’s additional U.S. engagement as part of a continuing rollout.

Market Pulse Summary

This announcement highlights continued U.S. commercialization of Pulsenmore’s home pregnancy ultraso...

Analysis

This announcement highlights continued U.S. commercialization of Pulsenmore’s home pregnancy ultrasound, adding TLC Perinatal in Maryland and extending reach into a practice managing about 2,000 pregnancies annually. It follows recent commercial deals in the U.S. and Israel that supported remote monitoring strategies. Investors may watch for additional U.S. contracts, concrete usage metrics, and revenue disclosures to assess how quickly these engagements translate into financial impact and broader clinical adoption.

Key Terms

maternal-fetal medicine, telehealth, fda clearance, clinical consensus

4 terms

maternal-fetal medicine medical

"TLC Perinatal PA, a maternal-fetal medicine and women's ultrasound practice"

A medical specialty that manages high-risk pregnancies and the health of both the pregnant person and the developing baby, providing advanced diagnostics, treatments and procedures to prevent or address complications. Investors watch this field because demand for related drugs, diagnostic tests, medical devices and specialist services rises with demographic trends, clinical breakthroughs and regulatory or reimbursement changes — like a specialized crew steering a ship through stormy waters to protect valuable cargo.

telehealth technical

"hybrid care pathway that incorporates telehealth and scheduled in-clinic visits"

Telehealth is the delivery of healthcare services and consultations remotely using video calls, phone, text messaging, or connected devices to monitor and transmit medical information. It matters to investors because it can reshape how patients access care, lower costs, and create new revenue streams or risks for healthcare providers, insurers and technology companies—similar to how online banking changed financial services—while also exposing businesses to reimbursement and regulatory shifts.

fda clearance regulatory

"Another Commercial Engagement Following FDA Clearance"

FDA clearance is the U.S. Food and Drug Administration’s official permission to market certain medical devices or diagnostic tests after reviewing evidence that they are as safe and effective as similar products already on the market. For investors, it’s like a product passing a required safety inspection — it reduces regulatory uncertainty, speeds commercial rollout, and can directly affect sales prospects, valuation, and partnership opportunities.

clinical consensus medical

"aligns with ACOG's 2025 Clinical Consensus by enabling remote monitoring"

Agreement among independent medical experts about how to interpret clinical evidence, diagnose a condition, or use a treatment, reached through review of studies, guidelines or professional discussion. For investors, clinical consensus helps predict whether a therapy or diagnostic will be widely adopted, covered by payers, or favored by regulators—similar to referees agreeing on the rules so a game can proceed smoothly and attract spectators.

AI-generated analysis. Not financial advice.

OMER, Israel, Feb. 9, 2026 /PRNewswire/ -- Pulsenmore Ltd. (NASDAQ: PLSM) (TASE: PLSM), a pioneer in home ultrasound technology, today announced a new commercial engagement with TLC Perinatal PA, a maternal-fetal medicine and women's ultrasound practice in Maryland, as part of its growing U.S. rollout.

In early February 2026, Pulsenmore, through its U.S. subsidiary, entered into a services agreement with TLC Perinatal PA, which operates in Silver Spring and Germantown, Maryland. Under the agreement, TLC Perinatal will incorporate Pulsenmore's Early Screening (ES) home ultrasound services into its care model, allowing patients to perform ultrasound scans at home as part of a physician-directed hybrid care pathway that incorporates telehealth and scheduled in-clinic visits.

The Company believes the engagement reflects increasing interest among U.S. maternal-fetal medicine practices in adopting patient-centric technologies that extend care beyond the clinic. Pulsenmore's solution combines home ultrasound with telehealth infrastructure, enabling clinicians to maintain clinical oversight while offering patients greater flexibility and continuity of care.

TLC Perinatal is a specialized maternal-fetal medicine practice focused on diagnostic imaging and consultative care for pregnancies. Led by Medical Director Richard Broth, MD, the practice manages approximately 2,000 pregnancies annually across its two Maryland locations and is recognized for its progressive approach to integrating new technologies into prenatal care.

"Pulsenmore's Home Ultrasound represents a vital step in expanding prenatal care access while enhancing convenience for all patients- it's a natural progression in our commitment to innovation. The device aligns with ACOG's 2025 Clinical Consensus by enabling remote monitoring of fetal health, personalizing care delivery, integrating patient preferences, and reducing office visits- all while maintaining or improving maternal and fetal outcomes through evidence-based practice," said Dr. Richie Broth, Medical Director of TLC Perinatal.

Dr. Elazar Sonnenschein, CEO of Pulsenmore, commented: "As we begin commercial operations in the United States, we are seeing strong engagement from practices that prioritize innovation and patient-centered care. Our collaboration with TLC Perinatal aims to demonstrate how maternal-fetal medicine teams can thoughtfully integrate home ultrasound into existing clinical workflows, offering patients greater flexibility while preserving physician oversight."

About Pulsenmore

Pulsenmore Ltd. is dedicated to revolutionizing maternal health through the development of home-use ultrasound technology that connect mothers and healthcare providers remotely. By leveraging advanced imaging and telemedicine, Pulsenmore makes prenatal care patient-centric, expanding access and improving continuity of care. For more information, visit www.pulsenmore.com.

Forward-Looking Statements

This press release contains forward-looking statements. In particular, statements using words such as "may," "seek," "will," "consider," "likely," "assume," "estimate," "expect," "anticipate," "intend," "believe," "contemplate," "do not believe," "aim," "goal," "due," "predict," "plan," "project," "continue," "potential," "positioned," "guidance," "objective," "outlook," "trends," "future," "could," "would," "should," "target," "on track" or their negatives or variations, and similar terminology and words of similar import, generally involve future or forward-looking statements. Such forward-looking statements include, but are not limited to, statements relating to the expected outcome of Pulsenmore's engagement with TLC. Forward-looking statements reflect Pulsenmore's current views, plans, or expectations with respect to future events or financial performance. They are inherently subject to significant business, economic, competitive, and other risks, uncertainties, and contingencies. Forward-looking statements are based on Pulsenmore's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict, including, but not limited to, the following: the Company's lack of operating history; the Company's current and future capital requirements and the Company's belief that its existing cash will be sufficient to fund its operations for more than one year from the date that the financial statements are issued; the Company's ability to manufacture, market and sell its products and to generate revenues; the Company's ability to maintain its relationships with key partners and grow relationships with new partners; the Company's ability to maintain or protect the validity of its U.S. and other patents and other intellectual property; the Company's ability to launch and penetrate markets in new locations and new market segments; the Company's ability to retain key executive members and hire additional personnel; the Company's ability to maintain and expand intellectual property rights; interpretations of current laws and the passages of future laws; the Company's ability to achieve greater regulatory compliance needed in existing and new markets; the Company's ability to achieve key performance milestones in its planned operational testing; the Company's ability to establish adequate sales, marketing and distribution channels; security, political and economic instability in the Middle East that could harm its business; and acceptance of the Company's business model by investors. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company's reports filed from time to time with the SEC, including, but not limited to, the risks, uncertainties and other factors included in the Company's Form 20-F (SEC File No. 001-43033), filed with the SEC on December 29, 2025. The inclusion of forward-looking statements in this or any other communication should not be considered as a representation by Pulsenmore or any other person that current plans or expectations will be achieved. Forward-looking statements speak only as of the date on which they are made, and Pulsenmore undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise, except as otherwise required by law.

Investor Contact:
Miri Segal-Scharia
MS-IR LLC
msegal@ms-ir.com

View original content:https://www.prnewswire.com/news-releases/pulsenmore-builds-us-momentum-with-another-commercial-engagement-following-fda-clearance-302682408.html

SOURCE Pulsenmore Ltd.

FAQ

What did Pulsenmore (PLSM) announce on February 9, 2026 about U.S. commercialization?

Pulsenmore announced a new commercial engagement with TLC Perinatal to deploy its Early Screening home ultrasound. According to Pulsenmore, the agreement integrates home ultrasound into a physician-directed hybrid care model combining telehealth and scheduled in-clinic visits in Maryland.

How will TLC Perinatal use Pulsenmore's Early Screening home ultrasound with PLSM technology?

TLC Perinatal will incorporate Pulsenmore's ES home ultrasound into patient care pathways under a services agreement. According to Pulsenmore, clinicians will maintain oversight via telehealth while patients perform home scans alongside scheduled clinic visits.

How many pregnancies does TLC Perinatal manage and why is that relevant to PLSM's rollout?

TLC Perinatal manages approximately 2,000 pregnancies annually across two Maryland locations. According to Pulsenmore, this patient volume offers a practical setting to demonstrate integration of home ultrasound into prenatal workflows and patient-centered monitoring.

Does Pulsenmore say the home ultrasound aligns with clinical guidance such as ACOG's 2025 consensus?

Pulsenmore says the home ultrasound aligns with ACOG's 2025 Clinical Consensus on remote monitoring and personalized prenatal care. According to Pulsenmore, the device supports remote fetal monitoring while aiming to preserve or improve maternal and fetal outcomes.

What is the expected impact of the Pulsenmore-TLC Perinatal agreement on patient care and clinician oversight?

The agreement is expected to increase patient convenience while preserving clinician oversight through telehealth and hybrid visits. According to Pulsenmore, the model aims to extend care beyond the clinic and provide continuity without sacrificing clinical supervision.